A Phase 2A Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of SQ109 in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis.

Trial Profile

A Phase 2A Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of SQ109 in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs SQ 109 (Primary) ; Rifampicin
  • Indications Pulmonary tuberculosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jan 2012 Planned end date changed from 1 Oct 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
    • 23 Aug 2011 New trial source identified and integrated (Pan-African Clinical Trials Registry record PACTR201009000252144).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top